Strattera (Atomoxetine) 10‑100 mg Capsules: Prescription Non-Stimulant Selective Noradrenaline Reuptake Inhibitor for ADHD in Children and Adults — Not a Controlled Substance

Information last reviewed: May 2026 — for educational purposes only.

Strattera (atomoxetine hydrochloride) was the first non-stimulant FDA-approved specifically for ADHD (approved 2002) and remains the paradigm of the non-stimulant approach. Unlike methylphenidate and amphetamine salts that primarily increase dopamine availability, atomoxetine selectively inhibits the noradrenaline (norepinephrine) reuptake transporter (NET) — boosting noradrenergic neurotransmission in the prefrontal cortex without direct dopaminergic stimulation in the striatum (the mesolimbic reward pathway). This selective noradrenergic mechanism accounts for both its efficacy in ADHD and its very low abuse potential — it produces no euphoria or pleasurable stimulant effects, has no street value, and is not a DEA Scheduled substance.

The key clinical trade-off of atomoxetine versus stimulants is efficacy versus tolerability profile and onset. Stimulants work within 30–60 minutes of the first dose; atomoxetine requires 4–8 weeks of consistent daily dosing before the full therapeutic benefit for ADHD symptoms becomes apparent — a critical counselling point to prevent premature discontinuation when patients feel no immediate effect. The long-term clinical benefit is comparable to stimulants in many patients, and atomoxetine may have advantages in patients with comorbid anxiety (where stimulants can worsen anxiety), tic disorders, or substance abuse history. It also provides 24-hour coverage including evening hours, where stimulant benefit typically wears off.

What Is Atomoxetine?

Atomoxetine is classified as a selective noradrenaline reuptake inhibitor (SNRI — distinct from the antidepressant SNRIs like venlafaxine which inhibit both serotonin and noradrenaline). By selectively inhibiting NET, it increases synaptic noradrenaline in the prefrontal cortex (PFC), improving PFC-mediated executive functions — working memory, impulse control, attentional focus, and cognitive flexibility — that are characteristically impaired in ADHD. The half-life of atomoxetine is 3–5 hours in most people (extensive metabolisers via CYP2D6); however, approximately 7–10% of the population are poor metabolisers (CYP2D6 PM) who have 5–10× higher plasma levels, more pronounced effects, and greater risk of side effects. These individuals may need substantially lower doses and experience greater cardiovascular (HR, BP) effects.

Prescription Status

Atomoxetine is prescription-only and not a controlled substance. It does not require Schedule II DEA prescriptions and can be written with refills — a practical advantage in patients where scheduling a monthly appointment for stimulant refills is a barrier to care. It is FDA-approved for children ≥6 years and adults.

Strengths and Available Forms

• Atomoxetine 10 mg capsule — starting dose; children <70 kg: start 0.5 mg/kg/day
• Atomoxetine 18 mg capsule
• Atomoxetine 25 mg capsule
• Atomoxetine 40 mg capsule
• Atomoxetine 60 mg capsule
• Atomoxetine 80 mg capsule
• Atomoxetine 100 mg capsule — near maximum approved dose; adults dose based on body weight or up to 100 mg/day (max 1.4 mg/kg or 100 mg, whichever is less)

Dosing: Children/adolescents ≤70 kg: Start 0.5 mg/kg/day for at least 3 days, then increase to target 1.2 mg/kg/day; maximum 1.4 mg/kg/day or 100 mg/day (whichever is less). Adults and children >70 kg: Start 40 mg/day, increase after ≥3 days to 80 mg/day; maximum 100 mg/day. Once or twice daily dosing. May be taken with or without food. Capsules should be swallowed whole — do not open.

Price of Strattera and Generic Atomoxetine

Generic atomoxetine became available from 2017 and is significantly less expensive than brand-name Strattera. The generic provides the same efficacy at substantially lower cost. Some insurance plans require prior authorisation for ADHD non-stimulants. Patient assistance programmes are available through the brand for uninsured patients meeting income criteria.

Frequently Asked Questions

What is the black box warning on atomoxetine and who is most at risk?

Atomoxetine carries a black box warning for increased risk of suicidal ideation in paediatric and adolescent patients (children and teenagers under 18). This warning is based on pooled analyses of short-term clinical trials in paediatric ADHD patients showing a small but statistically increased rate of suicidal thoughts (approximately 0.4% vs 0% on placebo) during the early weeks of treatment — consistent with warnings added to antidepressants. No completed suicides were reported in these trials. Physicians must counsel families about this risk, monitor closely for clinical worsening, mood changes, unusual behaviour, agitation, or suicidal thoughts — especially during the first few months of treatment and at each dose increase. Patients and families should be instructed to contact the prescriber immediately if such symptoms emerge.

Why does atomoxetine take 4–8 weeks to work and what should patients expect in the meantime?

Stimulants work acutely by rapidly flooding synapses with dopamine/noradrenaline; the effect appears within an hour. Atomoxetine works by gradually building up steady-state noradrenaline levels in PFC synapses and by producing adaptive changes in noradrenergic receptor density and sensitivity that require weeks to develop. During the first 4 weeks, patients may experience initial side effects (reduced appetite, mild GI upset, moodiness, fatigue) without yet experiencing the ADHD benefit — potentially leading to early discontinuation if not counselled about this lag. Physicians should schedule a follow-up visit at 4–6 weeks to assess benefit, not at 1–2 weeks. Partial improvement may be seen at 4 weeks; full benefit often requires 8–12 weeks. Persistence through the initial period is critical to achieving the therapeutic outcome.

Is atomoxetine effective for adults with ADHD?

Yes — atomoxetine is FDA-approved for adult ADHD and has significant clinical trial evidence supporting efficacy in adults. Meta-analyses show effect sizes of approximately 0.4–0.6 in adult ADHD, which is somewhat lower than stimulants (effect sizes 0.6–1.0) but clinically meaningful. Atomoxetine's advantages in adults include: no scheduled-drug prescribing hassle; once-daily dosing (versus multiple doses for IR stimulants); 24-hour symptom coverage without evening rebound; efficacy for comorbid adult depression/anxiety (modest antidepressant effect from noradrenaline enhancement); and appropriate choice when substance abuse history or diversion risk makes stimulant prescribing inadvisable. Off-label adult use is common and actively managed by psychiatrists and primary care physicians.

← Back to ADHD Medications